N/A
N=30
Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Central Retinal Vein Occlusion With Macular Edema
Bottom Line
View on ClinicalTrials.gov: NCT04812977 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Oct 2022
Primary outcome: Primary: Visual Acuity — 0.32; 0.44 logMAR units
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Group A (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Hayatabad Medical Complex
- Primary completion
- Dec 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Acuity |
0.32; 0.44 | — |
| SECONDARY Central Foveal Thickness |
264.4; 271.01 | — |
Summary
To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.
Eligibility Criteria
Inclusion Criteria
- Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.
Exclusion Criteria
- previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.
Data sourced from ClinicalTrials.gov (NCT04812977). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.